SLDE Reports Q3: What Happens After the Bullish Setup

Slide Insurance Holdings reported Q3 results on October 28, and the question now is whether the unusually bullish options positioning that preceded the print was warranted.

The pre-earnings signal in options was striking. The put/call ratio heading into the release had collapsed to 0.54, nearly 1.35 standard deviations below its 20-day average of 0.87. That placed it close to the most call-heavy reading of the past year. The rotation was sharp: through mid-October the PCR was running above 1.0 on consecutive sessions, then from October 19 onward calls dominated flow in a way that was difficult to ignore. That bullish lean has held post-announcement, with the ratio ticking modestly to 0.54 on the October 27 close. The stock ended the day at $28.39, down 2.4% on the session but still 3.8% higher on the week and up 23% over the past month, a strong run heading into the print.

The lending market offers no amplifying story in either direction. Availability has loosened slightly to 474%, meaning roughly four to five shares remain available to lend for every one already borrowed. That is down from around 548% a week ago but still well above any level that would signal squeeze pressure. Cost to borrow is 0.51% annually, essentially unchanged and firmly in "easy borrow" territory. Short interest has edged up about 1.2% on the week to 6.2% of the free float, a level that is meaningful for a $3.3 billion market cap insurer but not extreme. The position has been grinding modestly higher since late September, rising from around 6.4 million shares to 7.8 million, yet the pace is gradual rather than aggressive. Bears are present but not pressing hard.

The Street's positioning reflects similar ambivalence. Analysts who cover the name are broadly constructive, with Citizens, Keefe Bruyette and Barclays all maintaining positive ratings and having lifted targets incrementally over the past few months. The most recent move, Citizens raising its target to $28 from $27 on October 12, leaves the consensus mean target at $27.80, roughly in line with the current price of $28.39. That is unusual: a stock up 23% in a month that has essentially caught up to where analysts think fair value is. Morgan Stanley moved to Equal-Weight in early July after a downgrade from Overweight, cutting its target to $20, a notably cautious outlier. The bull case rests on the 89% premium growth CAGR and the expansion into New York and New Jersey. The bear case centres on reinsurance cost exposure and coastal catastrophe risk, both of which remain live concerns given the company's Florida-heavy book.

Valuation has moved with the stock. The price-to-book multiple has risen 0.34 points over the past 30 days to roughly 1.95 times, and the PE has expanded by 1.5 turns to 7.7 times. Those are not stretched levels in absolute terms. The earnings yield factor ranks in the 81st percentile and the EV/EBIT score sits at the 95th percentile, both pointing to a stock the market is pricing cheaply relative to its earnings power. The short score of 61 is moderately elevated, ranking in only the 8th percentile of the universe on that metric, which reflects the 6% float short, modest days-to-cover of around 5.9, and the recent drift higher in borrowed shares.

One ownership note worth flagging: CEO Bruce Lucas controls around 31% of shares outstanding as of September 30, having added roughly 1 million shares in the quarter. His total reported stake, including related entities, is close to 40% of the class per the most recent Schedule 13G filed in October 2025. That filing is now over 12 months old. As stakes are as-last-disclosed around the 5% threshold, the actual current figure could differ. The Chief Risk Officer made a series of open-market sales in mid-to-late October totalling around $380,000, all under a pre-arranged 10b5-1 plan, so those carry limited signal as a measure of conviction.

Wikipedia pageview data from ORTEX Alt Data shows retail attention running at a z-score of 3.0 against the stock's own 90-day history, one of the stronger attention spikes in the dataset. That is a measure of interest, not a revenue indicator, but it does confirm that the Q3 catalyst has drawn an unusually wide audience. With the results now in hand, the next watch point is how the Street reacts: whether analysts, particularly the Morgan Stanley outlier, revisit their targets in the days ahead given the stock is now trading above most published price objectives.